SPOKE 4
Preclinical and clinical breakthrough theranostic and treatments for cancer
Innovative therapeutic solutions for tumors that cannot be treated with conventional approaches and advancements in preclinical and clinical research methods.
Partner
SPOKE LEADER
Giovanni Livolti
Università degli Studi di Catania
Objectives
- Development of innovative therapeutic solutions and clinically relevant multi-functional approaches
- Generation of a therapeutic platform focused on the treatment of cancer that includes state-of-the-art treatments (e.g. multi-functional nanoformulations with greater ability to reach the target, FLASH and ULTRA-FLASH therapy) and a new Boron Neutron Capture Therapy (BNCT) facility.
Methodologies
Spoke 4 includes multi-functional therapeutic solutions to develop innovative and personalized cancer treatments. In brief, the following methodologies will be developed:
Multiple multi-functional therapeutic nanoformulations with better therapeutic results by exploiting innovative targets
New methods to overcome biological barriers and the current limited effectiveness of nanoformulations (e.g. ultrasonically mediated sonoporation)
FLASH therapy
Boron Neutron Capture Therapy (BNCT - Boron Neutron Capture Therapy)
Spoke 4
Pilot-Based Programme
Pilot 4.1, Pilot 4.4, Pilot 4.5, Pilot 4.6 and Pilot 4.9
They are dedicated to the development of innovative therapeutic solutions for the treatment of cancer. The selected approaches will generate a platform where differential therapeutic solutions will be studied in parallel to maximise the opportunity for combined and personalised therapies for cancers. In addition, Pilot 4.9 will enable the creation of a new boron neutron capture therapy (BNCT) - an emerging treatment to improve the therapeutic outcome of low-response cancers.
Pilot 4.2, Pilot 4.3 and Pilot 4.7
They are dedicated to the generation of diagnostic solutions that cover the entire tumor of interest (from cells to tissues). This approach will allow to identify new targets of interest for patient stratification and to better validate the effect of proposed therapies. Pilot 4.8 includes an AI-based system to evaluate and maximize the effectiveness of the therapeutic platform developed within the Spoke.
SPOKE 4
Contacts
